HER2/neu Peptide Vaccine GLSI-100

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A cancer peptide vaccine comprised of the epitope GP2, a nine amino acid peptide (amino acids 654-662) derived from the tumor-associated antigen (TAA) HER2/neu (ErbB-2) and the immune-adjuvant granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the HER2/neu peptide vaccine GLSI-100, GP2 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER2/neu antigen, which may result in the inhibition of proliferation of HER2/neu-expressing tumor cells. HER2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF enhances the CTL-mediated immune response against HER2/neu.

**Synonyms:** - GLSI 100 - GLSI-100 - GLSI100 - GP2 Peptide/GM-CSF GLSI-100 - HER2/neu Peptide GP2/GM-CSF GLSI-100 - Peptide Vaccine GLSI-100